Immunization of HLA-A201 Patients With Metastatic Melanoma Using a Combination of Immunodominant Peptides From Three Melanoma Antigens, MART-1, GP100 and Tyrosinase
Clinical trial NCT00001685 · COMPLETED
Trial details
- NCT number
- NCT00001685
- Sponsor
- National Cancer Institute (NCI)
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 1997-11-01
- Enrollment
- 114
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.